(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Knesset sets special panel to fast-track Karhi’s communications reform - 2A single shot of HPV vaccine may be enough to fight cervical cancer, study finds
- 3'Stranger Things' made him a heartthrob. He left Hollywood anyway.
- 4Turning into a Distributed Writer: My Composing Process
- 5Find Successful Magnificence Items for Sparkling Skin
- Ukraine to get up to 100 French-made Rafale fighter jets
- At least 171 measles cases confirmed in 9 states, CDC data shows
- Guaranteeing Quality Medical care with Federal medical care Benefit Plans.
- 2025 among world's three hottest years on record, WMO says
- Figure out How to Back Your Rooftop Substitution
- It's your last chance to subscribe to Paramount+ before they raise their prices: Here's how to lock in current pricing
- Elanco's drug gets emergency nod to treat deadly flesh-eating parasite in cats
- Worldwide Objections Ideal For A Golf Outing
- The most effective method to Settle on Informed Conclusions about Senior Insuranc.
